ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    Unknown
    Membrane depolarization induces p140trk and NGF responsiveness, but not p75LNGFR, in MAH cells (1992)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 1992-07-17
    Description: Nerve growth factor (NGF) is required for the maturation and survival of sympathetic neurons, but the mechanisms controlling expression of the NGF receptor in developing neuroblasts have not been defined. MAH cells, an immortalized sympathoadrenal progenitor cell line, did not respond to NGF and expressed neither low-affinity NGF receptor (p75) nor p140trk messenger RNAs. Depolarizing concentrations of potassium chloride, but none of a variety of growth factors, induced expression of p140trk but not p75 messenger RNA. A functional response to NGF was acquired by MAH cells under these conditions, suggesting that expression of p75 is not essential for this response. Depolarization also permitted a relatively high proportion of MAH cells to develop and survive as neurons in fibroblast growth factor and NGF. These data establish a relation between electrical activity and neurotrophic factor responsiveness in developing neurons, which may operate in the functioning of the mature nervous system as well.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Birren, S J -- Verdi, J M -- Anderson, D J -- NS23476/NS/NINDS NIH HHS/ -- New York, N.Y. -- Science. 1992 Jul 17;257(5068):395-7.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Division of Biology, California Institute of Technology, Pasadena 91125.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/1321502" target="_blank"〉PubMed〈/a〉
    Keywords: Blotting, Northern ; Cell Line ; Cell Line, Transformed ; Cell Membrane/*physiology ; Dose-Response Relationship, Drug ; Membrane Potentials ; Nerve Growth Factors/*biosynthesis ; Neurons/*metabolism/*physiology ; Potassium Chloride/pharmacology ; Proto-Oncogene Proteins/*biosynthesis ; RNA, Messenger/*biosynthesis ; Receptor, trkA ; Receptors, Cell Surface/*biosynthesis ; Receptors, Nerve Growth Factor ; Signal Transduction ; Time Factors ; Tretinoin/pharmacology
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 2
    facet.materialart.
    Unknown
    Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7 (2011)
    Nature Publishing Group (NPG)
    Details
    Publication Date: 2011-03-04
    Description: Microtubules have pivotal roles in fundamental cellular processes and are targets of antitubulin chemotherapeutics. Microtubule-targeted agents such as Taxol and vincristine are prescribed widely for various malignancies, including ovarian and breast adenocarcinomas, non-small-cell lung cancer, leukaemias and lymphomas. These agents arrest cells in mitosis and subsequently induce cell death through poorly defined mechanisms. The strategies that resistant tumour cells use to evade death induced by antitubulin agents are also unclear. Here we show that the pro-survival protein MCL1 (ref. 3) is a crucial regulator of apoptosis triggered by antitubulin chemotherapeutics. During mitotic arrest, MCL1 protein levels decline markedly, through a post-translational mechanism, potentiating cell death. Phosphorylation of MCL1 directs its interaction with the tumour-suppressor protein FBW7, which is the substrate-binding component of a ubiquitin ligase complex. The polyubiquitylation of MCL1 then targets it for proteasomal degradation. The degradation of MCL1 was blocked in patient-derived tumour cells that lacked FBW7 or had loss-of-function mutations in FBW7, conferring resistance to antitubulin agents and promoting chemotherapeutic-induced polyploidy. Additionally, primary tumour samples were enriched for FBW7 inactivation and elevated MCL1 levels, underscoring the prominent roles of these proteins in oncogenesis. Our findings suggest that profiling the FBW7 and MCL1 status of tumours, in terms of protein levels, messenger RNA levels and genetic status, could be useful to predict the response of patients to antitubulin chemotherapeutics.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Wertz, Ingrid E -- Kusam, Saritha -- Lam, Cynthia -- Okamoto, Toru -- Sandoval, Wendy -- Anderson, Daniel J -- Helgason, Elizabeth -- Ernst, James A -- Eby, Mike -- Liu, Jinfeng -- Belmont, Lisa D -- Kaminker, Josh S -- O'Rourke, Karen M -- Pujara, Kanan -- Kohli, Pawan Bir -- Johnson, Adam R -- Chiu, Mark L -- Lill, Jennie R -- Jackson, Peter K -- Fairbrother, Wayne J -- Seshagiri, Somasekar -- Ludlam, Mary J C -- Leong, Kevin G -- Dueber, Erin C -- Maecker, Heather -- Huang, David C S -- Dixit, Vishva M -- CA043540/CA/NCI NIH HHS/ -- CA80188/CA/NCI NIH HHS/ -- England -- Nature. 2011 Mar 3;471(7336):110-4. doi: 10.1038/nature09779.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA. ingrid@gene.com〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21368834" target="_blank"〉PubMed〈/a〉
    Keywords: Animals ; Apoptosis/drug effects ; Cell Cycle Proteins/genetics/*metabolism ; Cell Line ; Cell Line, Tumor ; Cell Transformation, Neoplastic/drug effects ; Drug Resistance, Neoplasm ; F-Box Proteins/genetics/*metabolism ; Fibroblasts ; Humans ; Mice ; Mitosis/drug effects ; Myeloid Cell Leukemia Sequence 1 Protein ; Paclitaxel/pharmacology ; Pharmacogenetics ; Phosphorylation/drug effects ; Polyploidy ; Proteasome Endopeptidase Complex/metabolism ; Protein Binding/drug effects ; Proto-Oncogene Proteins c-bcl-2/deficiency/genetics/*metabolism ; RNA, Messenger/genetics/metabolism ; Tubulin/*metabolism ; Tubulin Modulators/*pharmacology ; Ubiquitin-Protein Ligases/deficiency/genetics/*metabolism ; Vincristine/pharmacology
    Print ISSN: 0028-0836
    Electronic ISSN: 1476-4687
    Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics
    Published by Nature Publishing Group (NPG)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 3
    facet.materialart.
    Unknown
    RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth (2010)
    Nature Publishing Group (NPG)
    Details
    Publication Date: 2010-02-05
    Description: Activating mutations in KRAS and BRAF are found in more than 30% of all human tumours and 40% of melanoma, respectively, thus targeting this pathway could have broad therapeutic effects. Small molecule ATP-competitive RAF kinase inhibitors have potent antitumour effects on mutant BRAF(V600E) tumours but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumour models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK. Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context. In BRAF(V600E) tumours, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumour growth. Notably, in KRAS mutant and RAS/RAF wild-type tumours, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumour growth in some xenograft models. Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP. These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain. On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context. Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Hatzivassiliou, Georgia -- Song, Kyung -- Yen, Ivana -- Brandhuber, Barbara J -- Anderson, Daniel J -- Alvarado, Ryan -- Ludlam, Mary J C -- Stokoe, David -- Gloor, Susan L -- Vigers, Guy -- Morales, Tony -- Aliagas, Ignacio -- Liu, Bonnie -- Sideris, Steve -- Hoeflich, Klaus P -- Jaiswal, Bijay S -- Seshagiri, Somasekar -- Koeppen, Hartmut -- Belvin, Marcia -- Friedman, Lori S -- Malek, Shiva -- England -- Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Genentech, South San Francisco, California 94080, USA. hatzivassiliou.georgia@gene.com〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/20130576" target="_blank"〉PubMed〈/a〉
    Keywords: Adenosine Triphosphate/metabolism ; Animals ; Benzamides/pharmacology ; Cell Line ; Cell Membrane/drug effects/metabolism ; Cell Proliferation/drug effects ; Diphenylamine/analogs & derivatives/pharmacology ; Enzyme Activation/drug effects ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Humans ; Indenes/pharmacology ; Indoles/pharmacology ; MAP Kinase Signaling System/*drug effects ; Mice ; Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors/metabolism ; Neoplasms/drug therapy/enzymology/metabolism/*pathology ; Protein Kinase Inhibitors/*pharmacology/therapeutic use ; Protein Multimerization ; Protein Structure, Tertiary ; Protein Transport/drug effects ; Proto-Oncogene Proteins/genetics/metabolism ; Proto-Oncogene Proteins B-raf/antagonists & ; inhibitors/chemistry/genetics/metabolism ; Proto-Oncogene Proteins c-raf/deficiency/genetics/metabolism ; Pyrazoles/pharmacology ; Sulfonamides/pharmacology ; Xenograft Model Antitumor Assays ; raf Kinases/*antagonists & inhibitors/chemistry/genetics/*metabolism ; ras Proteins/genetics/metabolism
    Print ISSN: 0028-0836
    Electronic ISSN: 1476-4687
    Topics: Biology , Chemistry and Pharmacology , Medicine , Natural Sciences in General , Physics
    Published by Nature Publishing Group (NPG)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
  • 4
    facet.materialart.
    Unknown
    The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes (1995)
    American Association for the Advancement of Science (AAAS)
    Details
    Publication Date: 1995-03-03
    Description: The neuron-restrictive silencer factor (NRSF) binds a DNA sequence element, called the neuron-restrictive silencer element (NRSE), that represses neuronal gene transcription in nonneuronal cells. Consensus NRSEs have been identified in 18 neuron-specific genes. Complementary DNA clones encoding a functional fragment of NRSF were isolated and found to encode a novel protein containing eight noncanonical zinc fingers. Expression of NRSF mRNA was detected in most nonneuronal tissues at several developmental stages. In the nervous system, NRSF mRNA was detected in undifferentiated neuronal progenitors, but not in differentiated neurons. NRSF represents the first example of a vertebrate silencer protein that potentially regulates a large battery of cell type-specific genes, and therefore may function as a master negative regulator of neurogenesis.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Schoenherr, C J -- Anderson, D J -- NS23476/NS/NINDS NIH HHS/ -- New York, N.Y. -- Science. 1995 Mar 3;267(5202):1360-3.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Division of Biology 216-76, California Institute of Technology, Pasadena 91125.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/7871435" target="_blank"〉PubMed〈/a〉
    Keywords: Amino Acid Sequence ; Animals ; Base Sequence ; Brain-Derived Neurotrophic Factor ; Cell Line ; Central Nervous System/chemistry/cytology/embryology ; DNA, Complementary/genetics ; DNA-Binding Proteins/analysis/chemistry/genetics/*physiology ; *Gene Expression Regulation ; Humans ; Intracellular Signaling Peptides and Proteins ; Membrane Proteins ; Mice ; Molecular Sequence Data ; Nerve Growth Factors/genetics ; Nerve Tissue Proteins/genetics ; Neurons/chemistry ; *Regulatory Sequences, Nucleic Acid ; Repressor Proteins/physiology ; Sodium Channels/genetics ; Stem Cells/chemistry ; Synapsins/genetics ; Transcription Factors/analysis/chemistry/genetics/*physiology ; Transcription, Genetic ; Transfection ; Zinc Fingers
    Print ISSN: 0036-8075
    Electronic ISSN: 1095-9203
    Topics: Biology , Chemistry and Pharmacology , Computer Science , Medicine , Natural Sciences in General , Physics
    Published by American Association for the Advancement of Science (AAAS)
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
    PAPER CURRENT
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...